Tag: 2016

  • Gareth Thomas – 2016 Parliamentary Question to the Ministry of Defence

    Gareth Thomas – 2016 Parliamentary Question to the Ministry of Defence

    The below Parliamentary question was asked by Gareth Thomas on 2016-01-25.

    To ask the Secretary of State for Defence, whether the Mott MacDonald Report 2012 on safety standards at RAF Northolt recommended that an Engineered Material Arresting System be installed at RAF Northolt; and if he will make a statement.

    Mr Philip Dunne

    The Engineered Material Arresting System (EMAS) is being scoped as a military infrastructure requirement commensurate with safety cases for military aircraft operating at RAF Northolt and the associated military aerodrome design standards utilised at the Station. I am withholding estimated costs for the EMAS project as it is at the pre-tender stage and disclosure would or would be likely to prejudice commercial interests.

    The Mott McDonald report has no opinion or relevance against the military aerodrome design criteria and safety cases in place at the Station or the current operation of RAF Northolt. Any infrastructure investment for military operational requirements will continue to be undertaken as necessary to support military and Government outputs.

  • Lord Alton of Liverpool – 2016 Parliamentary Question to the Department of Health

    Lord Alton of Liverpool – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Alton of Liverpool on 2016-02-22.

    To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 11 February (HL5647), whether the UK Stem Cell Bank holds appropriately detailed records on the origin of stem cell lines deposited therein; and if so, when any bona fide stem cells derived from trophectoderm were recorded as having been deposited in the UK Stem Cell Bank.

    Lord Prior of Brampton

    When human embryonic stem cell lines are deposited at UK Stem Cell Bank originators of the cells complete a detailed application that includes the scientific characteristics of the cells. Applications to deposit cell lines derived in the United Kingdom are reviewed to confirm that they comply with Human Fertilisation and Embryology Authority licencing by the steering committee. The cell lines currently deposited with UK Stem Cell Bank do not include human stem cell lines derived from trophectoderm.

  • Roger Godsiff – 2016 Parliamentary Question to the Department for International Development

    Roger Godsiff – 2016 Parliamentary Question to the Department for International Development

    The below Parliamentary question was asked by Roger Godsiff on 2016-03-10.

    To ask the Secretary of State for International Development, what steps the UK is taking to support the provision of climate risk insurance to people who are most vulnerable to the impact of climate change; and how much funding she plans to allocate to such support.

    Mr Nick Hurd

    The UK is a leader in climate risk insurance and is committed to contributing to meeting the G7 “InsuResilience” collective target set out in the Elmau declaration of helping up to an additional 400 million people in the most vulnerable developing countries to gain access to climate risk insurance by 2020.

    Recent UK support for the provision of climate risk insurance includes contributions of up to £100m to African Risk Capacity (ARC), up to £15m for the Pacific Catastrophe Risk Assessment and Financing Initiative, £5m to help developing countries with disaster contingency planning backed by risk finance, £3m of technical support to the Government of the Philippines to help them implement their financial protection and insurance strategy, and £1.4m to support livestock insurance for pastoralists in Kenya.

  • Lord Hunt of Kings Heath – 2016 Parliamentary Question to the Department of Health

    Lord Hunt of Kings Heath – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Hunt of Kings Heath on 2016-04-14.

    To ask Her Majesty’s Government why the South Warwickshire Clinical Commissioning Group is going ahead with its proposals to tender out its £227 million Out of Hospital Programme in the light of (1) the review of such contracts that is being conducted following the review by David Stout into the causes of the termination of the Uniting Care Partnership Contract, and (2) the criticism by the local acute Foundation Trust of that process.

    Lord Prior of Brampton

    NHS England advises that it is reviewing how this type of contract is assured. We understand that South Warwickshire Clinical Commissioning Group’s procurement has been placed on hold until the appropriate assurance is in place.

  • Greg Mulholland – 2016 Parliamentary Question to the Department for Transport

    Greg Mulholland – 2016 Parliamentary Question to the Department for Transport

    The below Parliamentary question was asked by Greg Mulholland on 2016-05-24.

    To ask the Secretary of State for Transport, how the £40 million that was allocated to the Supertram scheme for Leeds that was cancelled in 2005 was spent.

    Claire Perry

    The Department of Transport did not provide any funding for the Leeds Supertram or Leeds New Generation Trolleybus schemes. Any expenditure committed so far is the responsibility of the promoters – West Yorkshire Combined Authority and Leeds City Council.

  • Rob Marris – 2016 Parliamentary Question to the Department for Communities and Local Government

    Rob Marris – 2016 Parliamentary Question to the Department for Communities and Local Government

    The below Parliamentary question was asked by Rob Marris on 2016-07-11.

    To ask the Secretary of State for Communities and Local Government, when he plans to respond to the letter to his Department from the hon. Member for Wolverhampton South West of 5 May 2016 on neighbourhood plans, reference ZA3476.

    Brandon Lewis

    I replied to the hon. Member on 11 July 2016.

  • Ian Austin – 2016 Parliamentary Question to the Department of Health

    Ian Austin – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Ian Austin on 2016-10-07.

    To ask the Secretary of State for Health, who is responsible for deciding which heroin addicts are provided with heroin in line with his Department’s policy set out on page 31 of the Modern Crime Prevention Strategy, published by his predecessor in March 2016.

    Nicola Blackwood

    The prescribing of injectable opioids, such as methadone or diamorphine (pharmaceutical heroin) as substitutes for illicit heroin, as outlined in the Government’s Modern Crime Prevention Strategy, published in March by the then Home Secretary, has been an option for many years but since the late 1960s, prescribing of diamorphine for the management of addiction has been restricted to licensed addiction specialists.

    The decision to prescribe injectable diamorphine for the treatment of dependence is a clinical matter, for a clinician to take in conjunction with the patient. Advice to guide these decisions is contained in Chapter 5 and Annex 8 of the 2007 UK Guidelines on the Clinical Management of Drug Misuse and Dependence. The guidelines advise that:

    – “injectable opioid treatment may be suitable for a small minority of patients who have failed in optimised oral treatment.”;

    – “clinicians providing injectable opioid treatment should encourage patients not to regard it as a lifelong treatment option and should regularly review their patients and the continuing necessity for this unusual and expensive treatment”; and

    – The use of diamorphine “alone does not constitute drug treatment…it should be seen as on element or pathway within wider packages of planned and integrated drug treatment”.

    The guidelines are currently being reviewed by an Expert Working Group, to take into account developments in the evidence base. In July 2016, the Expert Working Group published their draft update for consultation. The consultation has closed and the responses are being considered by the Expert Working Group.

    Diamorphine is licensed as a medicine by the Medicines and Healthcare products Regulatory Agency. Clinicians wishing to legally prescribe it for the treatment of dependence need to obtain a licence for that purpose from the Home Office and to comply with all other legislation relevant to the safe management, use and supply of medicines which are controlled drugs.

  • Sadiq Khan – 2016 Parliamentary Question to the Department for Education

    Sadiq Khan – 2016 Parliamentary Question to the Department for Education

    The below Parliamentary question was asked by Sadiq Khan on 2016-01-25.

    To ask the Secretary of State for Education, how many childcare places there were in each London borough on 1 January of each year from 2010 to 2016.

    Mr Sam Gyimah

    Local authorities are required to report annually to elected council members on how they are meeting their duty to secure sufficient childcare, and make this report available and accessible to parents. The Department does not hold borough level estimates centrally.

    The Department for Education’s Childcare and Early Years Providers Survey[1] collects data on all registered childcare places, including those in maintained schools and nurseries. However, data is only available at a national and regional level.

    [1] https://www.gov.uk/government/statistics/childcare-and-early-years-providers-survey-2013

  • Lord Clement-Jones – 2016 Parliamentary Question to the Department of Health

    Lord Clement-Jones – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Clement-Jones on 2016-02-22.

    To ask Her Majesty’s Government what assessment they have made of how many more cancer medicines will be available to patients as a result of the proposals for a revised Cancer Drugs Fund to be effective from 1 April.

    Lord Prior of Brampton

    We have made no such assessment.

    NHS England and the National Institute for Health and Care Excellence (NICE) recently consulted on draft proposals for the future direction of the Cancer Drugs Fund (CDF). The consultation outlines a new system, fully integrated into the NICE appraisal process, where the CDF becomes a transitional fund – with clear criteria for entry and exit. The consultation closed on 11 February 2016.

    NHS England has advised that the operational detail of the new scheme will be developed over the coming months, informed by detailed analysis and consideration of the consultation responses received. A new Standard Operating Procedure for the CDF will be published by June 2016. Any changes to the list of available treatments through the Fund as a result of the changes in model will be published in due course.

    NHS England has advised that it is optimistic that a greater number of cancer drugs will be funded from baseline commissioning in the future as a consequence of more appropriate pricing arrangements proposed by pharmaceutical manufacturers and the new CDF being able to address issues as to longer term patient outcomes in order to give such drugs the chance of re-appraisal by NICE with greater certainty as to clinical and cost effectiveness.

  • Robert Jenrick – 2016 Parliamentary Question to the Department for Transport

    Robert Jenrick – 2016 Parliamentary Question to the Department for Transport

    The below Parliamentary question was asked by Robert Jenrick on 2016-03-10.

    To ask the Secretary of State for Transport, what information he holds on whether Network Rail plans to release a contribution to the cost of a disabled access footbridge at Bingham railway station in Nottinghamshire.

    Claire Perry

    The Department for Transport does not hold information on Network Rail’s plans for funding towards the cost of an accessible footbridge at Bingham station.